South Korea-based bio-healthcare company Dx&Vx (DXVX) announced on Thursday the acceleration of its development programme for a universal COVID-19 vaccine, following the recent acquisition of related technology.
The company says that the vaccine is designed to provide immunity against both current and future variants of the coronavirus, amid a new wave of COVID-19 cases worldwide.
DXVX secured the universal vaccine technology late last year. The vaccine under development uses a virus-like particle (VLP) platform, which is claimed to offer greater stability and ease of storage compared to mRNA vaccines.
Theoretically, it has the potential to prevent infections caused by all known and future COVID-19 variants.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses